
External referencing and pharmaceutical price negociation
Garcia Marinoso, Begona; Jelovac, Izabella; Olivella, Pau (2011), External referencing and pharmaceutical price negociation, Health Economics, 20, 6, p. 737-756. http://dx.doi.org/10.1002/hec.1630
View/ Open
Type
Article accepté pour publication ou publiéDate
2011Journal name
Health EconomicsVolume
20Number
6Publisher
Wiley
Pages
737-756
Publication identifier
Metadata
Show full item recordAbstract (EN)
External referencing (ER) imposes a price cap for pharmaceuticals, based on prices of identical or comparable products in foreign countries. Suppose a foreign country (F) negotiates prices with a pharmaceutical firm, whereas a home country (H) can either negotiate prices independently or implement ER, based on the foreign price. We show that country H prefers ER if copayments in H are relatively high. This preference is reinforced when H's population is small. Irrespective of relative country sizes, ER by country H harms country F. Our model is inspired by the wide European experience with this cost-containment policy. Namely, in Europe, drug authorization and price negotiations are carried out by separate agencies. We confirm our main results in two extensions. The first one allows for therapeutic competition between drugs. In the second one, drug authorization and price negotiation take place in a single agency.Subjects / Keywords
pharmaceuticals; external referencing; price negotiationRelated items
Showing items related by title and author.
-
Chebbi, Houssem Eddine; Boujelbene, Younes; Ayadi, Inès (2008) Communication / Conférence
-
Milone, Mario (2018-12-03) Thèse
-
Charruau, Paul (2022-06-29) Thèse
-
Nefla, Ons (2021-06-30) Thèse